The Monash Alfred Psychiatry Research Centre (the Research Centre) is conducting a double-blind clinical trial assessing a novel treatment for fibromyalgia that uses magnetic fields to stimulate neurons in the brain called rTMS.
Estimates from 2012 showed that in Australia about 6.1 million people were affected by musculoskeletal conditions, with an projected rate of increase of 43% by 2032. This high incidence costs the country a total of $55.1 billion in health care and lost productivity costs. Musculoskeletal conditions are more prevalent in Australia than cancer, heart disease or diabetes.
“Despite the prevalence of fibromyalgia and the economic burden it imposes, there are no effective treatments, which is likely due to the fact that there is a complete absence of etiologically-driven treatment options. Existing treatments, such as medications, are not designed specifically to treat fibromyalgia, are largely ineffective and result in a range of adverse side effects,” said